Get the Stockscreener App
7.45
5.37%
0.38
After Hours:
7.46
0.010
+0.13%
Sagimet Biosciences Inc stock is traded at $7.45, with a volume of 544.02K.
It is up +5.37% in the last 24 hours and up +5.52% over the past month.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$7.07
Open:
$7.12
24h Volume:
544.02K
Relative Volume:
0.29
Market Cap:
$460.05M
Revenue:
$2.00M
Net Income/Loss:
$-43.51M
P/E Ratio:
-5.5535
EPS:
-1.3415
Net Cash Flow:
$-39.73M
1W Performance:
+4.05%
1M Performance:
+5.52%
6M Performance:
+22.33%
1Y Performance:
-27.25%
1-Day Range:
$7.025
$7.59
1-Week Range:
$6.86
$7.59
52-Week Range:
$4.50
$10.46
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
7.45 | 436.59M | 2.00M | -43.51M | -39.73M | -1.3415 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Initiated | Rodman & Renshaw | Buy |
| Feb-03-26 | Initiated | Guggenheim | Buy |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Aug-11-25 | Initiated | Wedbush | Outperform |
| Aug-07-25 | Resumed | H.C. Wainwright | Buy |
| Jul-24-25 | Initiated | Canaccord Genuity | Buy |
| Dec-06-24 | Initiated | Oppenheimer | Outperform |
| Nov-12-24 | Initiated | UBS | Buy |
| Jun-28-24 | Downgrade | Goldman | Buy → Neutral |
| May-02-24 | Initiated | H.C. Wainwright | Buy |
| Mar-25-24 | Initiated | Leerink Partners | Outperform |
| Aug-08-23 | Initiated | Goldman | Buy |
| Aug-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Aug-08-23 | Initiated | Piper Sandler | Overweight |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
View All
Sagimet Biosciences Inc Stock (SGMT) Latest News
Sagimet Biosciences Inc (SGMT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sagimet Biosciences Inc (SGMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sagimet Biosciences Inc (SGMT) Cash Flow - TradingKey
SGMT|Sagimet Biosciences Inc|Price:7.420|Chg%:+0.350 - TradingKey
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits
Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A – DUS:0O2 - TradingView
Sagimet Biosciences Market Sentiment - Benzinga España
TradingKey - TradingKey
Sagimet Biosciences Inc.Series A Revenue Breakdown – NASDAQ:SGMT - TradingView
Sagimet, PNC, United Rentals, Rani, Southern Copper Insider Shake-Up - TipRanks
Sagimet Biosciences Inc (SGMT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Top Sagimet Executives Quietly Unlock Major Value in Recent Stock Moves - TipRanks
Sagimet Biosciences CEO David Happel disposes of $497,067 in shares By Investing.com - Investing.com South Africa
Insider Sell: George Kemble Sells Shares of Sagimet Biosciences Inc (SGMT) - GuruFocus
Form 4 Sagimet Biosciences Inc For: 22 July By Investing.com - Investing.com Nigeria
Sagimet Biosciences officer Rozek sells $81,832 in shares By Investing.com - Investing.com Nigeria
Sagimet Biosciences CEO David Happel disposes of $497,067 in shares - Investing.com
Sagimet Biosciences officer Rozek sells $81,832 in shares - Investing.com India
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Sagimet Biosciences (SGMT) Dips 1.26% as Stock Hovers Near Key Support ZoneWave Truncation - dars.gov.et
Sagimet updates acne pipeline and funding strategy - TipRanks
Sagimet to advance denifanstat Phase 3 in US; $104.5M cash, $175M offering funds operations through 2028 - TradingView
Sagimet Biosciences Inc. SEC Filing (Jul 20, 2026) - Stock Titan
Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A – MUN:0O2 - TradingView
Sagimet (SGMT) Has Fresh Index Visibility, but the Real Test Is Still Denifanstat Execution - AlphaStreet
Sagimet Biosciences Joins Russell 3000 and 2000 Indexes - sekbernews.id
Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion - Yahoo Finance
Sagimet Biosciences Inc. Series A Q1 2026 Earnings: Narrower-than-Expected Loss as EPS Surprises PositivelyNet Profit Margin - DonanımHaber
Sagimet Biosciences(SGMT) Stock Options Chain | Quotes & News - Moomoo
Sagimet Biosciences Inc. (SGMT) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock Uptick - DonanımHaber
Price to earnings forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A – SWB:0O2 - TradingView
Sagimet Biosciences (SGMT) Rallies 2% as Shares Test Key Resistance Near $8.00Short Setup Alerts - dars.gov.et
Sagimet Biosciences (SGMT) Financials 2026Income Statement and Balance Sheet - MarketBeat
Sagimet Biosciences to join Russell 3000 and Russell 2000 as part of 2026 index reconstitution - Traders Union
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Raises Target Price to $31 - Moomoo
Sagimet Therapeutics: Buy Rating Affirmed as Clinically De‑Risked FASN Franchise Advances; Price Target Raised to $31 - TipRanks
Sagimet Biosciences Inc.(NasdaqGM:SGMT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2500 Growth Benchmark - marketscreener.com
Sagimet Biosciences Added to Russell Indexes - marketscreener.com
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2000 Index - marketscreener.com
Sagimet Biosciences added to Russell 2000 and 3000 indexes By Investing.com - Investing.com South Africa
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2000 Value Benchmark - marketscreener.com
Sagimet Biosciences Inc. Class A Actuals & Estimates (NASDAQ:SGMT) - TradingView
Sagimet Biosciences Inc.(NasdaqGM:SGMT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Sagimet Biosciences (SGMT) Joins Russell 3000 and Russell 2000 I - GuruFocus
Sagimet Biosciences added to Russell 2000 and 3000 indexes - Investing.com
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2000 Growth Benchmark - marketscreener.com
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 3000E Growth Benchmark - marketscreener.com
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2500 Index - marketscreener.com
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):